Enzyme Produces Product Which Is Part Of Another Reaction System (e.g., Cyclic Reaction, Cascade Reaction, Etc.) Patents (Class 435/7.91)
  • Patent number: 10795648
    Abstract: Systems and methods of the disclosed subject matter are directed to receiving, at a server having a mobile application publishing platform, application information. The server determines a plurality of product modules based on the received application information. An affinity score for each of the product modules is dynamically determined from the received application information. The server provides at least one of the plurality of product modules for selection based on the dynamically determined affinity score. The server receives a selection of at least one of the plurality of product modules that is provided for selection based on the dynamically determined affinity score. The server generates an application that integrates the selected at least one of the plurality of product modules with the received application information so that the generated application includes a feature provided by the integrated at least one of the plurality of product modules.
    Type: Grant
    Filed: November 30, 2017
    Date of Patent: October 6, 2020
    Assignee: Google LLC
    Inventors: Michael Petrillo, Atul Kumar
  • Patent number: 10753931
    Abstract: In one aspect, an assay test strip includes a test label that specifically binds a target analyte and a control label that is free of any specific binding affinity for the target analyte and has a different optical characteristic than the test label. In another aspect, an assay test strip includes a test label that specifically binds a target analyte and at least one non-specific-binding label that is free of any specific binding affinity for the target analyte. Systems and methods of reading assay test strips also are described.
    Type: Grant
    Filed: March 24, 2009
    Date of Patent: August 25, 2020
    Assignee: ALVERIX, INC.
    Inventors: Patrick T. Petruno, John F. Petrilla, Michael J. Brosnan, Rong Zhou, Daniel B. Roitman
  • Patent number: 10544449
    Abstract: Multi-biotinylated reactants are provided which can be used in divalent complexes for various applications such as colocalization, labeling, immobilization, and purification. Methods for constructing, purifying, and using the bis-biotinylated reactants are also provided. In certain embodiments, two bis-biotinylated reactants are bound to a single streptavidin tetramer to provide a complex having a 1:1 stoichiometry with respect to the bis-biotinylated reactants.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: January 28, 2020
    Assignee: Pacific Biosciences of California, Inc.
    Inventors: Gene Shen, Natasha Popovich, Erik Miller, Satwik Kamtekar, Keith Bjornson, Jeremiah Hanes, Stephen Yue, Lubomir Sebo, Zhong Wang
  • Patent number: 9952230
    Abstract: A problem to be solved by the present invention is to inhibit a nonspecific agglutination reaction in an agglutination test using a monoclonal antibody having a property of specifically biding to PIVKA-II and a monoclonal antibody having a property of specifically biding to prothrombin as well as two types of carrier particles carrying these monoclonal antibodies. The nonspecific agglutination reaction can be inhibited by adding certain divalent metal ions to a reaction solution containing the monoclonal antibody having a property of specifically biding to PIVKA-II and the monoclonal antibody having a property of specifically biding to prothrombin as well as the two types of carrier particles carrying these monoclonal antibodies.
    Type: Grant
    Filed: May 23, 2012
    Date of Patent: April 24, 2018
    Assignee: SEKISUI MEDICAL CO., LTD.
    Inventors: Takuji Matsumoto, Mitsuaki Yamamoto
  • Patent number: 9874576
    Abstract: The present invention relates to novel lateral flow devices using two dimensional features, preferably, uniform two dimensional test and control features, and the methods for detecting an analyte using the lateral flow devices, and processes for making the lateral flow devices.
    Type: Grant
    Filed: April 12, 2013
    Date of Patent: January 23, 2018
    Assignee: SYMBOLICS, LLC
    Inventors: Brendan O'Farrell, Thomas C. Tisone
  • Patent number: 9874556
    Abstract: The present invention relates to novel lateral flow devices using two dimensional features, preferably, uniform two dimensional test and control features, to provide flow control information, to function as an internal control and/or to provide internal calibration information for the test device. The present invention also relates to methods for using the lateral flow devices to provide flow control information, to function as an internal control and/or to provide internal calibration information for the test device.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: January 23, 2018
    Assignee: Symbolics, LLC
    Inventors: Brendan O'Farrell, Thomas C. Tisone
  • Patent number: 9851366
    Abstract: The present invention relates to novel lateral flow devices using two dimensional features, preferably, uniform two dimensional test and control features, and the methods for detecting an analyte using the lateral flow devices, and processes for making the lateral flow devices.
    Type: Grant
    Filed: April 12, 2013
    Date of Patent: December 26, 2017
    Assignee: SYMBOLICS, LLC
    Inventors: Brendan O'Farrell, Thomas C. Tisone
  • Patent number: 9797019
    Abstract: The present invention relates generally to an assay for detecting and differentiating multiple analytes, if present, in a single fluid sample, including devices and methods therefore.
    Type: Grant
    Filed: October 30, 2015
    Date of Patent: October 24, 2017
    Assignee: Quidel Corporation
    Inventors: Paul Lambotte, Michael Cerrito, Cecille Ramirez
  • Patent number: 9382316
    Abstract: The present invention provides a humanized anti-EMAP II antibody, the use of the humanized antibody, and pharmaceutical compositions containing the humanized antibody. The humanized anti-EMAP II antibody shows reduced immunogenicity and increased half-life while having similar or improved antigen binding capacity compared to the parent monoclonal antibody. Thus, the humanized anti-EMAP II antibody of the present invention can be more effectively used as a diagnostic reagent for EMAP II and a therapeutic agent for diseases that are mediated by EMAP II.
    Type: Grant
    Filed: July 14, 2011
    Date of Patent: July 5, 2016
    Assignees: Cell & Bio Co., Ltd., L & K Biomed Co., Ltd.
    Inventor: Kang-Jun Yoon
  • Patent number: 9012136
    Abstract: There is provided mechanisms for the detection of an analyte in a sample. The mechanisms utilize at least a first measurement channel comprising a detection reactant corresponding to the analyte to be detected, and at least a microstructure associated with the first measurement channel. When the mechanisms are in use, the sample is introduced into the first measurement channel and propagated by way of the first measurement channel towards the microstructure. If the analyte is present in the sample, the analyte interacts with the detection reactant to form a networked product, and the microstructure is configured to filter the networked product.
    Type: Grant
    Filed: October 30, 2008
    Date of Patent: April 21, 2015
    Assignee: International Business Machines Corporation
    Inventors: Emmanuel Delamarche, Daniel J. Solis
  • Patent number: 9005887
    Abstract: There is provided mechanisms for the detection of an analyte in a sample. The mechanisms utilize at least a first measurement channel comprising a detection reactant corresponding to the analyte to be detected, and at least a microstructure associated with the first measurement channel. When the mechanisms are in use, the sample is introduced into the first measurement channel and propagated by way of the first measurement channel towards the microstructure. If the analyte is present in the sample, the analyte interacts with the detection reactant to form a networked product, and the microstructure is configured to filter the networked product.
    Type: Grant
    Filed: April 30, 2012
    Date of Patent: April 14, 2015
    Assignee: International Business Machines Corporation
    Inventors: Emmanuel Delamarche, Daniel J. Solis
  • Patent number: 8916353
    Abstract: The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a PWD circovirus, also are provided. Method for selecting compounds capable of modulating the viral infection are further provided. Pharmaceutical, including vaccine, compositions for preventing and/or treating viral infections caused by PWD circovirus and the use of vectors for preventing and/or treating diseases also are provided.
    Type: Grant
    Filed: October 20, 2011
    Date of Patent: December 23, 2014
    Assignee: Zoetis W LLC
    Inventors: André Jestin, Emmanuel Albina, Pierre Le Cann, Philippe Blanchard, Evelyne Hutet, Claire Arnauld, Catherine Truong, Dominique Mahe, Roland Cariolet, François Madec
  • Publication number: 20140220566
    Abstract: The invention concerns in vitro proteomic analysis of cells to determine the sensitizing potential (including allergic potential) of compounds on said cells. Several protein markers are provided that allow assays to be performed to determine whether a chemical has a sensitizing potential of contact and/or respiratory sensitizers.
    Type: Application
    Filed: June 18, 2012
    Publication date: August 7, 2014
    Applicant: ELECTROPHORETICS LIMITED
    Inventors: Emma Lahert, Stephan Jung, Petra Budde, Hans-Dieter Zucht, Stefan Selzer, Sasa Koncarevic, Karsten Kuhn, Ian Pike
  • Publication number: 20140221241
    Abstract: Compositions and methods are provided for the use of nanoparticles, which may be referred to herein as mass dots, as mass tags for probes such as antibodies, aptamers, nucleic acids, etc. in multiplexed bioassays with ICP-MS detection.
    Type: Application
    Filed: February 5, 2014
    Publication date: August 7, 2014
    Inventors: Garry P. Nolan, Erin F. Simonds, Sean C. Bendall, Bernd Bodenmiller
  • Publication number: 20140212407
    Abstract: The present disclosure relates to the treatment, e.g. reduction, of body fat mass levels for example in overweight and obese subjects. The present disclosure also relates to weight control in a subject where obesity should be avoided. Disclosed herein are methods of reducing body fat mass e.g. reducing obesity or preventing weight gain and agents used in such methods whereby the agents inhibit a sulphur containing amino acid. Also included in the present disclosure include, without being limited to, methods for determining regimes for the treatment of obesity as well as other subject matter.
    Type: Application
    Filed: September 5, 2013
    Publication date: July 31, 2014
    Applicant: Isis Innovation Limited
    Inventors: Amany ELSHORBAGY, Helga Margareta REFSUM
  • Patent number: 8785144
    Abstract: Disclosed is an analysis method comprising the steps of: (a) reacting a substance to be analyzed with at least a specific partner which exhibits a selective interaction with the substance, converting a soluble substance to an insoluble substance by an insolubilization reaction, in correlation with the amount of the substance to be analyzed contained in a sample, and depositing the insoluble substance on a sensing part, and (b) electrically analyzing the insoluble substance deposited on the sensing part, wherein at least one of steps (a) and (b) is carried out under flow conditions.
    Type: Grant
    Filed: March 17, 2009
    Date of Patent: July 22, 2014
    Assignee: Mitsubishi Chemical Medience Corporation
    Inventors: Yasuo Ifuku, Nagamoto Murai
  • Publication number: 20140170068
    Abstract: In various embodiments methods are provided for identifying a mammal having an elevated risk for an adverse cardiac event (e.g. an MI) and/or determining the prognosis for the mammal. In certain embodiments the methods comprise determining, or causing to be determined, the presence and/or level of antibodies that bind a malondialdehyde-acetaldehyde adduct (MAA adduct) in a biological sample from the mammal, where an elevated level of anti-MAA adduct antibodies, as compared to the level found in a normal healthy mammal is an indicator that that said mammal has one or more atherosclerotic lesions and/or is at elevated risk for a myocardial infarction.
    Type: Application
    Filed: March 12, 2012
    Publication date: June 19, 2014
    Applicant: BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA
    Inventors: Geoffrey M. Thiele, Daniel R. Anderson, Michael J. Duryee
  • Patent number: 8703417
    Abstract: The invention is directed to enhanced methods for detecting an analyte of interest in situ, by immunoassay, or by hybridization comprising binding an enzyme-labeled conjugate molecule to an analyte of interest in the presence of a redox-inactive reductive species and a soluble metal ion. The enzyme catalyzes the conversion of the inactive reductive species to an active reducing agent, which in turn reduces the metal ion to a metal atom thereby providing an enhanced means of detecting the analyte via metal deposition.
    Type: Grant
    Filed: June 21, 2012
    Date of Patent: April 22, 2014
    Assignee: Ventana Medical Systems, Inc.
    Inventors: Christopher Bieniarz, Michael Farrell
  • Patent number: 8679772
    Abstract: The invention provides a highly sensitive immunoassay for detection of a biological species. The immunoassay comprises exposing an electrode to an analyte liquid putatively containing the biological species so as to couple the biological species, if present in the analyte liquid, to a binding antibody on the electrode. The electrode comprises a binding antibody and an anchor group, each being coupled to an electrically conductive substrate, said binding antibody being capable of binding to the biological species and said anchor group being capable of binding to a redox polymer.
    Type: Grant
    Filed: June 6, 2008
    Date of Patent: March 25, 2014
    Assignee: Agency for Science, Technology and Research
    Inventors: Zhiqiang Gao, Jie Zhang
  • Patent number: 8658361
    Abstract: Disclosed is a method for in situ detection of one or more target nucleic acids based on a combination of an in situ hybridization (ISH) assay method and a general ISH signal amplification method. This new method produces high signal intensity and while keeps low background noise of signal amplification. The result can be consistently reproduced and the method can be easily adopted for routine clinic diagnostic use. Further, the invention relates to a kit, comprising the components of the ISH assay and a general ISH signal amplification assay, for sensitive detection of one or more target nucleic acids.
    Type: Grant
    Filed: October 21, 2011
    Date of Patent: February 25, 2014
    Assignee: Advanced Cell Diagnostics, Inc.
    Inventors: Xingyong Wu, Huei-Yu Fay Wang, Nan Su, Li-Chong Wang, Yuling Luo
  • Patent number: 8652795
    Abstract: The present disclosure relates to a mutant lactate oxidase having increased stability, a nucleic acid encoding the mutant lactate oxidase, an expression vector comprising the nucleic acid, a host cell comprising the nucleic acid or the expression vector, a method of determining lactate in a sample, the use of the mutant lactate oxidase for determining lactate, a device for determining lactate in a sample using the mutant lactate oxidase and a kit for determining lactate comprising the mutant lactate oxidase.
    Type: Grant
    Filed: September 18, 2012
    Date of Patent: February 18, 2014
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Stefan Leitgeb, Thomas Meier, Bernd Nidetzky, Bernhard Schaffar, Thomas Stoisser
  • Patent number: 8642283
    Abstract: The present invention provides an assay for the identification of agents which can modulate TOR-mediated phosphorylation of substrate proteins. The assays of the invention utilize substrate proteins whose amino acid sequence contains the Ser/Thr motif recognized by TOR. Naturally occurring TOR which may be used in the methods of the invention include TOR isolated from a variety of species, particularly mammalian tissues.
    Type: Grant
    Filed: May 26, 2006
    Date of Patent: February 4, 2014
    Assignee: Sanford-Burnham Medical Research Institute
    Inventor: Robert T. Abraham
  • Patent number: 8637257
    Abstract: The present invention relates to methods for identifying agents capable of inhibiting the expression or activity of proteins involved in the processes modulating osteoclastogenesis, which inhibition is useful in the prevention and/or treatment of bone and joint degenerative diseases and diseases involving aberrant activity or differentiation of osteoclasts. In particular, the present invention provides methods for identifying agents for use in the prevention and/or treatment of rheumatoid arthritis.
    Type: Grant
    Filed: June 19, 2008
    Date of Patent: January 28, 2014
    Assignee: Galapagos NV
    Inventors: Reginald Christophe Xavier Brys, Nick Ernest René Vandeghinste
  • Publication number: 20140023698
    Abstract: Methods for determining dosage of HER2-targeted anthracycline-containing immunoliposomes are disclosed, as are methods of treating cancer patients with HER2-positive tumors using dosages so determined. Upon administration, the dosages share the low cardiotoxicity profile of standard dosages of non-immunoliposomal (untargeted), anthracycline-containing liposomes.
    Type: Application
    Filed: June 6, 2013
    Publication date: January 23, 2014
    Inventors: Joseph G. Reynolds, Kenneth J. Olivier, JR., Bart S. Hendriks, Thomas Wickham, Stephan Klinz, Elena Geretti
  • Patent number: 8609349
    Abstract: The present invention provides compositions and methods for detecting the activation states of components of signal transduction pathways in tumor cells. Information on the activation states of components of signal transduction pathways derived from use of the invention can be used for cancer diagnosis, prognosis, and in the design of cancer treatments.
    Type: Grant
    Filed: April 4, 2012
    Date of Patent: December 17, 2013
    Assignee: Nestec S.A.
    Inventors: Sharat Singh, Jeanne Harvey, Phillip Kim, Xinjun Liu, Limin Liu, Robert Barham, Bruce Neri
  • Patent number: 8530170
    Abstract: The present invention is directed to electronic methods of detecting target analytes such that upon binding of the target analyte a shift in electrochemical potential is seen. This assay relies on the use of an electroactive moiety (“EAM”) that is attached to an electrode and comprises a self-immolative moiety, whose presence gives the EAM a first E0, and whose absence, upon irreversible cleavage gives the EAM a second E0. This difference is detected, and if such change occurs, it is an indication of the presence of a target analyte.
    Type: Grant
    Filed: August 9, 2010
    Date of Patent: September 10, 2013
    Assignee: OHMX Corporation
    Inventor: Paul A. Bertin
  • Patent number: 8526001
    Abstract: An instrument for measuring and analyzing surface plasmon resonance on a sensor surface has a polarized light source optically connected to the sensor surface by a plurality of optical elements, including in one embodiment an optical telescope that transfers light from a rotatable reflecting surface to the sensor surface. Selective positioning of a cylindrical lens into a first position within the path of light transforms collimated light to a rectangular wedge that is incident upon the sensor surface at numerous angles. In another embodiment, the light source is operated as a laser to excite fluorescence on the sensor surface and the fluorescence is selectively directed to a detector by appropriate optical elements positioned in specific configurations.
    Type: Grant
    Filed: January 28, 2013
    Date of Patent: September 3, 2013
    Assignee: Ciencia, Inc.
    Inventors: George N. Gibson, Ernest F. Guignon, Michael T. Reilly
  • Patent number: 8497136
    Abstract: A device and method for detecting the presence of hemoglobin in a biological sample, more particularly, the presence of blood in a fecal sample as an indicator of upper or lower gastrointestinal tract bleeding.
    Type: Grant
    Filed: May 29, 2012
    Date of Patent: July 30, 2013
    Assignee: Quest Diagnostics Investments Incorporated
    Inventor: Howard Milne Chandler
  • Patent number: 8450080
    Abstract: The present invention provides methods and compositions for monitoring cofactors and metabolites of a metabolic pathway of interest. The subject compositions and methods are particularly suited for monitoring the mevalonate pathway in a variety of cells. The invention also provides fermentation methods for the production of isoprenoids.
    Type: Grant
    Filed: January 28, 2009
    Date of Patent: May 28, 2013
    Assignee: Amyris, Inc.
    Inventors: Sunil Bajad, Michael Leavell
  • Patent number: 8404459
    Abstract: The invention pertains to a method of measuring A? protofibrils in a sample. The method includes the steps of (a) providing a labeled monoclonal antibody or fragment thereof that binds wildtype A? 42/40 protofibril and A?42/40 Arc protofibril and has no or little cross-reactivity to A? 42/40 monomers with an agent that generates a measurable signal, (b) contacting said labeled antibody or fragment thereof with the fluid or tissue having or suspected of comprising A? protofibrils, and (c) measuring the amount of protofibrils bound to the antibody by measuring the signal generated by the agent.
    Type: Grant
    Filed: December 23, 2011
    Date of Patent: March 26, 2013
    Assignee: BioArctic Neuroscience AB
    Inventors: Pär Gellerfors, Lars Lannfelt
  • Patent number: 8368897
    Abstract: An instrument for measuring and analyzing surface plasmon resonance on a sensor surface has a polarized light source optically connected to the sensor surface by a plurality of optical elements, including in one embodiment an optical telescope that transfers light from a rotatable reflecting surface to the sensor surface. Selective positioning of a cylindrical lens into a first position within the path of light transforms collimated light to a rectangular wedge that is incident upon the sensor surface at numerous angles. In another embodiment, the light source is operated as a laser to excite fluorescence on the sensor surface and the fluorescence is selectively directed to a detector by appropriate optical elements positioned in specific configurations.
    Type: Grant
    Filed: August 21, 2009
    Date of Patent: February 5, 2013
    Assignee: Ciencia, Inc.
    Inventors: Michael T. Reilly, Ernest F. Guignon, George N. Gibson
  • Patent number: 8357494
    Abstract: The invention concerns anti-clusterin oligoclonal antibodies able to recognize and bind in a selective and specific way antigenic epitopes of clusterin isoforms to be used in tumors diagnosis and in the prediction of their malignancy grade, diagnostic method and related kits.
    Type: Grant
    Filed: February 17, 2005
    Date of Patent: January 22, 2013
    Assignees: Universita' Delgi Studi “Tor Vergate”, Institute Fisioterapici Ospitalieri
    Inventors: Luigi Giusto Spagnoli, Sabina Pucci, Elena Bonanno, Flavia Pichiorri, Gennaro Citro
  • Publication number: 20130004971
    Abstract: Proteins respectively having the amino acid sequences represented by SEQ ID NOs: 1, 17 and 32; structural genes respectively encoding the proteins, preferably respectively having the nucleotide sequences represented by SEQ ID NOs: 2, 18 and 33; an antibody capable of specifically binding to feline-derived cystatin C, feline-derived ?2 microglobulin or feline-derived ?1 microglobulin; a kit for diagnosing feline nephropathy, containing the antibody of the present invention; and a method for diagnosing feline nephropathy using the antibody of the present invention.
    Type: Application
    Filed: December 16, 2010
    Publication date: January 3, 2013
    Inventor: Fumio Hoshi
  • Patent number: 8323982
    Abstract: Fluid analyte sensors include a photoelectrocatalytic element that is configured to be exposed to the fluid, if present, and to respond to photoelectrocatalysis of at least one analyte in the fluid that occurs in response to impingement of optical radiation upon the photoelectrocatalytic element. A semiconductor light emitting source is also provided that is configured to impinge the optical radiation upon the photoelectrocatalytic element. Related solid state devices and sensing methods are also described.
    Type: Grant
    Filed: May 7, 2007
    Date of Patent: December 4, 2012
    Assignee: Valencell, Inc.
    Inventors: Steven Francis LeBoeuf, Jesse Berkley Tucker, Michael Edward Aumer
  • Patent number: 8309345
    Abstract: Provided is a method for detecting an antigen without use of a labeled-antibody. A support having an antibody and a multi-copper oxidase CueO immobilized thereon is brought into contact with a first buffer solution containing the antigen, a current is measured by a potentiostat method using the support and a second buffer solution, and when the measured current is greater than or equal to 1.5×(blank value), it is determined that the antigen exists. The second buffer solution contains a substrate of the CueO and has an ionic strength falling within a range of not less than 0.3 mM and not more than 1.0 mM.
    Type: Grant
    Filed: November 15, 2011
    Date of Patent: November 13, 2012
    Assignee: Panasonic Corporation
    Inventors: Kazuaki Nishio, Nozomu Matsukawa, Shigeo Yoshii
  • Patent number: 8298835
    Abstract: The present invention identifies biomarkers that are diagnostic of nerve cell injury, organ injury, and/or neuronal disorders. Detection of different biomarkers of the invention are also diagnostic of the degree of severity of nerve injury, the cell(s) involved in the injury, and the subcellular localization of the injury.
    Type: Grant
    Filed: June 11, 2008
    Date of Patent: October 30, 2012
    Assignee: University of Florida Research Foundation, Inc.
    Inventors: Ka-Wang (Kevin) Wang, Ming Chen Liu
  • Patent number: 8198036
    Abstract: A device and method for detecting the presence of hemoglobin in a biological sample, more particularly, the presence of blood in a fecal sample as an indicator of upper or lower gastrointestinal tract bleeding.
    Type: Grant
    Filed: March 2, 2010
    Date of Patent: June 12, 2012
    Assignee: Quest Diagnostics Investments Incorporated
    Inventor: Howard Chandler
  • Patent number: 8198033
    Abstract: The invention provides methods and materials for observing protein fragments generated during apoptosis in order to observe this process in mammalian cells. Embodiments of the invention can be used for example to observe apoptosis in order to examine the sensitivity of a mammalian cancer cell to apoptosis inducing agents.
    Type: Grant
    Filed: June 20, 2007
    Date of Patent: June 12, 2012
    Assignee: Genentech, Inc.
    Inventors: Cary D. Austin, David A. Lawrence, Avi Ashkenazi
  • Patent number: 8183005
    Abstract: The present inventors examined the inhibitory activity against HCV replicon of myriocin, fumonisin B1, and ceramide trafficking inhibitor HPA-12, which are compounds derived from microorganisms such as those of the genus Aureobasidium, and found that these compounds have the effect of inhibiting the replication of HCV replicon RNAs or inhibiting the expression of HCV proteins. The present inventors further performed serine palmitoyltransferase knockdown experiments using siRNAs, and results showed that HCV replicon activity and HCV protein expression were significantly inhibited in cells with suppressed LCB1 expression. Thus, sphingolipid biosynthesis was found to be involved in HCV infection. This showed that HCV infection can be treated or prevented by inhibiting enzyme activities involved in the process of sphingolipid biosynthesis by adding compounds or knocking down a gene.
    Type: Grant
    Filed: August 11, 2005
    Date of Patent: May 22, 2012
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Masayuki Sudo, Hiroshi Sakamoto
  • Patent number: 8148095
    Abstract: The atypical antipsychotic drugs (AAPDs) have markedly enhanced the treatment of schizophrenias but their use has been hindered by the major weight gain elicited by some AAPDs. We found that orexigenic AAPDs potently and selectively activate hypothalamic AMP kinase (AMPK), an action abolished in mice with deletion of histamine H1 receptors. These findings afford a means of developing better therapeutic agents and provide insight into the hypothalamic regulation of food intake.
    Type: Grant
    Filed: September 10, 2007
    Date of Patent: April 3, 2012
    Assignees: The Johns Hopkins University, The University of Vermont College of Medicine
    Inventors: Solomon H. Snyder, Alex Huang, Cory Teuscher, Sangwon Kim
  • Patent number: 8148171
    Abstract: A method for the multiplexed diagnostic and genetic analysis of enzymes, DNA fragments, antibodies, and other biomolecules comprises the steps of constructing an appropriately labeled beadset, exposing the beadset to a clinical sample, and analyzing the combined sample/beadset by flow cytometry. Flow cytometric measurements are used to classify, in real-time, beads within an exposed beadset and textual explanations, based on the accumulated data obtained during real-time analysis, are generated for the user. A secondary reagent, such as a metal or magnetic particle, is added to the beadset to assist in the analysis. Detection techniques, such as such as light scatter, Rayleigh scatter, Raman scatter, surface plasmon resonance, magnetic induction, or magnetoresistance are used to detect the particle labels.
    Type: Grant
    Filed: December 31, 2004
    Date of Patent: April 3, 2012
    Assignee: Luminex Corporation
    Inventors: Don J. Chandler, Van S. Chandler
  • Patent number: 8114624
    Abstract: The present invention pertains to the domain of brain diseases, and provides novel markers and methods for diagnosing a brain alteration in an individual, especially in patients suffering from neurodegenerative diseases such as Alzheimer's disease. The present invention also provides tools for evaluating the probability, for an individual, of developing the disease, as well as a target for identifying new drugs for treating neurodegenerative diseases such as Alzheimer's disease. In particular, the invention provides a genetic marker based on combination of two single nucleotide polymorphism, at positions ?389 and ?241 of the ornithine transcarbamylase (OTC) gene.
    Type: Grant
    Filed: April 18, 2007
    Date of Patent: February 14, 2012
    Assignees: Genoscreen, Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Philippe Amouyel, Jean-Charles Lambert, Stéphanie Ferreira
  • Patent number: 8067181
    Abstract: Human MELK genes are identified as modulators of the RAC pathway, and thus are therapeutic targets for disorders associated with defective RAC function. Methods for identifying modulators of RAC, comprising screening for agents that modulate the activity of MELK are provided.
    Type: Grant
    Filed: August 12, 2004
    Date of Patent: November 29, 2011
    Assignee: Exelixis, Inc.
    Inventors: Lisa Kadyk, George Ross Francis, Kim Lickteig, Timothy S. Heuer
  • Patent number: 8048642
    Abstract: Methods of activating an apo-peroxidase are provided. The methods include the steps of providing a solution comprising an apo-peroxidase and a heme choline ester, hydrolyzing the heme choline ester with a choline esterase, and converting the apo-peroxidase to active peroxidase. The methods disclosed herein also provide for detecting the presence of an analyte in a sample. The methods include providing a binder capable of specifically binding the analyte wherein the binder is attached to a solid surface, applying the sample to the solid surface under conditions that permit binder-analyte binding, adding a choline esterase-conjugated binder that binds to the analyte, adding an apo-peroxidase, a heme choline ester, a peroxide, and a peroxide-activated signal generator, and detecting the signal produced by the peroxide-activated signal generator. An associated kit and components are also provided.
    Type: Grant
    Filed: December 18, 2007
    Date of Patent: November 1, 2011
    Assignee: General Electric Company
    Inventors: Thomas Pirrie Treynor, Anup Sood, Sean Richard Dinn
  • Patent number: 8043820
    Abstract: The present invention provides methods of identifying markers indicative of the risk of developing a neurodevelopmental disorder caused in part by antibody- or autoantibody-mediated damage of neural tissue, including autism spectrum disorder (ASD). The invention further provides methods of diagnosing whether an individual has a neurodevelopmental disorder, including an ASD, and methods for determining the risk that a mother's future offspring will develop an a neurodevelopmental disorder, including an ASD.
    Type: Grant
    Filed: November 7, 2008
    Date of Patent: October 25, 2011
    Assignee: The Regents of the University of California
    Inventors: David G. Amaral, Judy Van de Water
  • Publication number: 20110236911
    Abstract: Improved apparatus, compositions, and methods for carrying out interferometry-based assays for detecting analytes in a sample through the use of a precipitating substrate to enhance an interferometry binding signal, and kits useful for carrying out these assays. Methods comprise providing an optical assembly comprising an optical element with a transparent material and adapted for coupling to a light source via a fiber, a first reflective surface and a second reflecting surface having a first analyte-binding molecule and separated from said first surface by a distance, d, exposing said optical element to a sample comprising said analyte, a second analyte binding molecule, and a precipitating substrate; and detecting a change in thickness at said first reflective surface thereby detecting said analyte in said sample. Kits include reagents for derivatizing assay components along with packaging and instructions for use.
    Type: Application
    Filed: March 18, 2011
    Publication date: September 29, 2011
    Applicant: FORTEBIO, INC.
    Inventors: Sae Hyun Choo, Weilei Ma, Jing Wei
  • Patent number: 8008026
    Abstract: The present invention relates to a method for differentially detecting a multimeric form from a monomeric form of a multimer-forming polypeptide in a biosample, which comprises the steps of: (a) preparing a carrier-capturing antibody conjugate by binding a capturing antibody to the surface of a solid phase carrier in a three dimensional manner, wherein the capturing antibody is capable of recognizing an epitope on the multimer-forming polypeptide; (b) preparing a detection antibody, wherein an epitope recognized by the detection antibody is present at a position in the multimer-forming polypeptide to cause a steric hindrance by the capturing antibody bound to its epitope to prevent the binding of the detection antibody to the multimer-forming polypeptide; (c) contacting simultaneously the carrier-capturing antibody conjugate and the detection antibody to the biosample; and (d) detecting the formation of a carrier-capturing antibody-multimeric form-detection antibody complex.
    Type: Grant
    Filed: April 20, 2007
    Date of Patent: August 30, 2011
    Assignee: Peoplebio, Inc.
    Inventors: Seong Soo Alexander An, Kun Taek Lim, Hyun Jung Oh
  • Patent number: 8008034
    Abstract: This invention is in the field of medical devices. Specifically, the present invention provides portable medical devices that allow real-time detection of analytes from a biological fluid. The methods and devices are particularly useful for providing point-of-care testing for a variety of medical applications. In particular, the medical device reduces interference with an optical signal which is indicative of the presence of an analyte in a bodily sample.
    Type: Grant
    Filed: March 13, 2007
    Date of Patent: August 30, 2011
    Assignee: Theranos, Inc.
    Inventors: Ian Gibbons, Michael O'Connell
  • Patent number: 8003341
    Abstract: The ATP amplification method is a method for amplifying and detecting a very trace amount of exogenous ATP by allowing a fusion protein (PPK-ADK) of a polyphosphate kinase and an adenylate kinase, the fusion protein not containing ADP, to act on a mixture of ATP, AMP, and a polyphosphate compound. Also provided is an ultrasensitive ATP amplification method by which ATP at a single cell level can be amplified and detected, and an ultrasensitive microbial assay based on this ATP amplification method.
    Type: Grant
    Filed: April 28, 2010
    Date of Patent: August 23, 2011
    Assignee: Japan Science and Technology Agency
    Inventor: Akio Kuroda
  • Patent number: 7998697
    Abstract: The present invention relates to a method for detecting the presence or non-presence of an endotoxin, characterized in that an OmpT protein is brought into contact with a sample suspected of containing an endotoxin and the protease activity of the OmpT protein is assayed. It also relates to a method for detecting early onset of septicaemia using the inventive method and a kit for performing the method.
    Type: Grant
    Filed: November 2, 2006
    Date of Patent: August 16, 2011
    Assignee: Bioproduce Sthlm AB
    Inventors: Gen Larsson, Per-Åke Nygren